SG11201908929VA - Synthekine compositions and methods of use - Google Patents
Synthekine compositions and methods of useInfo
- Publication number
- SG11201908929VA SG11201908929VA SG11201908929VA SG11201908929VA SG 11201908929V A SG11201908929V A SG 11201908929VA SG 11201908929V A SG11201908929V A SG 11201908929VA SG 11201908929V A SG11201908929V A SG 11201908929VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- california
- pct
- rule
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5406—IL-4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) W I PO I PCT mu °mons °nolo onolommllomoiflo Hs (10) International Publication Number WO 2018/182935 Al (51) International Patent Classification: A61K 38/00 (2006.01) C07K 14/52 (2006.01) A61K 38/19 (2006.01) GO1N 33/68 (2006.01) Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (21) International Application Number: PCT/US2018/021301 (22) International Filing Date: 07 March 2018 (07.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/479,993 31 March 2017 (31.03.2017) US (71) Applicant: THE BOARD OF TRUSTEES OF THE LE- LAND STANFORD JUNIOR UNIVERSITY [US/US]; Office of the General Counsel, Building 170, 3rd Floor, Main Quad P.O. Box 20386, Stanford, California 94305-2038 (US). (72) Inventors: GONZALEZ, Ignacio Moraga; 2042 Yale Street, Palo Alto, California 94306 (US). GARCIA, Kenan Christopher; 580 Kenwood Drive, Menlo Park, California 94025 (US). (74) Agent: SHERWOOD, Pamela J.; Bozicevic, Field & Francis LLP, 201 Redwood Shores Parkway, Suite 200, Redwood City, California 94065 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, 1-1 KM, ML, MR, NE, SN, TD, TG). M Declarations under Rule 4.17: 01 of inventorship (Rule 4.17(iv)) co 1-1 (54) Title: SYNTHEKINE COMPOSITIONS AND METHODS OF USE (57) : Engineered synthekines and methods of use thereof are provided.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762479993P | 2017-03-31 | 2017-03-31 | |
PCT/US2018/021301 WO2018182935A1 (en) | 2017-03-31 | 2018-03-07 | Synthekine compositions and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201908929VA true SG11201908929VA (en) | 2019-10-30 |
Family
ID=63677897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201908929V SG11201908929VA (en) | 2017-03-31 | 2018-03-07 | Synthekine compositions and methods of use |
Country Status (11)
Country | Link |
---|---|
US (2) | US20210260162A1 (en) |
EP (1) | EP3600372A4 (en) |
JP (1) | JP2020511988A (en) |
KR (1) | KR20190133707A (en) |
CN (1) | CN110582293A (en) |
AU (2) | AU2018243536B2 (en) |
CA (1) | CA3056600A1 (en) |
MX (1) | MX2019010984A (en) |
SG (1) | SG11201908929VA (en) |
WO (1) | WO2018182935A1 (en) |
ZA (1) | ZA201906169B (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3955956A1 (en) | 2019-04-19 | 2022-02-23 | Synerkine Pharma B.V. | Therapeutic crosslinking of cytokine receptors |
JP2022548069A (en) * | 2019-09-11 | 2022-11-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Chimeric Orthogonal Receptor Proteins and Methods of Use |
WO2022031884A2 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il2rg binding molecules and methods of use |
JP2023538518A (en) | 2020-08-05 | 2023-09-08 | シンセカイン インコーポレイテッド | IL10Rb binding molecules and methods of use |
WO2022031885A2 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il10ra binding molecules and methods of use |
AU2021320226A1 (en) | 2020-08-05 | 2023-03-23 | Synthekine, Inc. | gp130 binding molecules and methods of use |
WO2022032006A2 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il2rb binding molecules and methods of use |
MX2023001490A (en) | 2020-08-05 | 2023-04-27 | Synthekine Inc | Il27rî± binding molecules and methods of use. |
WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
US12012441B2 (en) | 2020-10-26 | 2024-06-18 | Neptune Biosciences Llc | Engineered human IL-21 cytokines and methods for using the same |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0659439B1 (en) * | 1993-12-24 | 2001-10-24 | MERCK PATENT GmbH | Immunoconjugates |
US7534585B2 (en) * | 2003-07-21 | 2009-05-19 | Transgene S.A. | Multifunctional cytokines |
US7635754B2 (en) * | 2004-09-22 | 2009-12-22 | Aerovance, Inc. | Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same |
EP2069401A4 (en) * | 2007-07-31 | 2011-02-23 | Medimmune Llc | Multispecific epitope binding proteins and uses thereof |
PT2794905T (en) * | 2011-12-20 | 2020-06-30 | Medimmune Llc | Modified polypeptides for bispecific antibody scaffolds |
JP6445434B2 (en) * | 2012-08-09 | 2018-12-26 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Superkine and synthekine: recycled cytokines with novel and enhanced signaling activity |
WO2015044386A1 (en) * | 2013-09-26 | 2015-04-02 | Ablynx Nv | Bispecific nanobodies |
-
2018
- 2018-03-07 US US16/492,555 patent/US20210260162A1/en not_active Abandoned
- 2018-03-07 KR KR1020197030606A patent/KR20190133707A/en not_active Application Discontinuation
- 2018-03-07 CA CA3056600A patent/CA3056600A1/en active Pending
- 2018-03-07 SG SG11201908929V patent/SG11201908929VA/en unknown
- 2018-03-07 EP EP18774902.3A patent/EP3600372A4/en active Pending
- 2018-03-07 CN CN201880029016.1A patent/CN110582293A/en active Pending
- 2018-03-07 WO PCT/US2018/021301 patent/WO2018182935A1/en active Application Filing
- 2018-03-07 JP JP2019553264A patent/JP2020511988A/en active Pending
- 2018-03-07 MX MX2019010984A patent/MX2019010984A/en unknown
- 2018-03-07 AU AU2018243536A patent/AU2018243536B2/en active Active
-
2019
- 2019-09-18 ZA ZA2019/06169A patent/ZA201906169B/en unknown
-
2023
- 2023-10-04 US US18/481,107 patent/US20240181009A1/en active Pending
-
2024
- 2024-04-22 AU AU2024202622A patent/AU2024202622A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN110582293A (en) | 2019-12-17 |
CA3056600A1 (en) | 2018-10-04 |
ZA201906169B (en) | 2021-01-27 |
JP2020511988A (en) | 2020-04-23 |
WO2018182935A1 (en) | 2018-10-04 |
KR20190133707A (en) | 2019-12-03 |
US20210260162A1 (en) | 2021-08-26 |
AU2018243536A1 (en) | 2019-10-03 |
US20240181009A1 (en) | 2024-06-06 |
EP3600372A4 (en) | 2020-12-30 |
AU2018243536B2 (en) | 2024-01-25 |
EP3600372A1 (en) | 2020-02-05 |
AU2024202622A1 (en) | 2024-05-16 |
MX2019010984A (en) | 2020-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201908929VA (en) | Synthekine compositions and methods of use | |
SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
SG11201804807VA (en) | Computer architecture and method for modifying data intake parameters based on a predictive model | |
SG11201903697WA (en) | Liver organoid compositions and methods of making and using same | |
SG11201807252QA (en) | Anti-lag-3 antibodies | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201910092TA (en) | Display method and device | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201910027YA (en) | Bispecific antibody against ox40 and ctla-4 | |
SG11201907023UA (en) | Method of reducing neutropenia | |
SG11201907381UA (en) | Building management system with declarative views of timeseries data | |
SG11201900653RA (en) | Silyl-bridged bis-biphenyl-phenoxy catalysts for olefin polymerization | |
SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201407682TA (en) | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | |
SG11201803403XA (en) | In situ-generated microfluidic isolation structures, kits and methods of use thereof | |
SG11201908179UA (en) | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | |
SG11201806110QA (en) | Treatment of cancer with combinations of immunoregulatory agents | |
SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
SG11201806485RA (en) | Pyrrolobenzodiazepine conjugates | |
SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
SG11201908053VA (en) | Rod and casing handler | |
SG11201804674UA (en) | Heteroarylhydroxypyrimidinones as agonists of the apj receptor | |
SG11201909083UA (en) | Piperidines as covalent menin inhibitors | |
SG11201908472VA (en) | Compositions and methods for activating nk cells |